Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLXTE-HAase02
- Development stage
- Phase 1
- Lead developer
- Henlius
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
HLXTE-HAase02 is a proprietary recombinant human hyaluronidase developed by Shanghai Henlius Biotech. Expressed in Chinese Hamster Ovary (CHO) cells, this enzyme has a molecular weight of approximately 49 kDa and is designed to facilitate the subcutaneous delivery of other therapeutic agents. It functions by temporarily depolymerizing hyaluronan (hyaluronic acid), a major polysaccharide component of the extracellular matrix in subcutaneous tissue. By breaking down hyaluronan, HLXTE-HAase02 reduces the viscosity of the interstitial gel and increases tissue permeability, allowing for the administration of larger volumes of fluids and enhancing the absorption and dispersion of co-administered biologics. This technology is primarily intended for formulation development to transition intravenous therapies to subcutaneous administration, potentially improving patient convenience and reducing healthcare resource utilization.
- Other names
- recombinant human hyaluronidaserHuPH20rHuPH-20rHuPH 20
Beyond the preview
Go deeper on HLXTE-HAase02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLXTE-HAase02.